242 related articles for article (PubMed ID: 35784363)
21. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
[TBL] [Abstract][Full Text] [Related]
22. Integration analysis identifies MYBL1 as a novel immunotherapy biomarker affecting the immune microenvironment in clear cell renal cell carcinoma: Evidence based on machine learning and experiments.
Wang T; Jian W; Xue W; Meng Y; Xia Z; Li Q; Xu S; Dong Y; Mao A; Zhang C
Front Immunol; 2022; 13():1080403. PubMed ID: 36591240
[TBL] [Abstract][Full Text] [Related]
23. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
[TBL] [Abstract][Full Text] [Related]
24. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
[TBL] [Abstract][Full Text] [Related]
25. Bioinformatics analysis of immune-related prognostic genes and immunotherapy in renal clear cell carcinoma.
Pan Z; Chang S; Chen S; Zhao D; Zou Z; Dai L; Hou Y; Zhang Q; Yang Y; Chen Z; Zhang W; Zhao Y
PLoS One; 2022; 17(11):e0272542. PubMed ID: 36417422
[TBL] [Abstract][Full Text] [Related]
26. M2-polarization-related CNTNAP1 gene might be a novel immunotherapeutic target and biomarker for clear cell renal cell carcinoma.
Li W; Meng X; Yuan H; Xiao W; Zhang X
IUBMB Life; 2022 May; 74(5):391-407. PubMed ID: 35023290
[TBL] [Abstract][Full Text] [Related]
27. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
[TBL] [Abstract][Full Text] [Related]
28. Cuproptosis-related gene
Huang S; Cai C; Zhou K; Wang X; Wang X; Cen D; Weng G
Aging (Albany NY); 2023 Nov; 15(21):12314-12329. PubMed ID: 37938155
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
[TBL] [Abstract][Full Text] [Related]
30. Decoding the Immune Microenvironment of Clear Cell Renal Cell Carcinoma by Single-Cell Profiling to Aid Immunotherapy.
Liu J; Xu J; Zhang T; Xu K; Bao P; Zhang Z; Xue K; He R; Ma L; Wang Y
Front Immunol; 2022; 13():791158. PubMed ID: 35812372
[TBL] [Abstract][Full Text] [Related]
31. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
32. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
[TBL] [Abstract][Full Text] [Related]
33. Inverse correlation of miR-27a-3p and CDH5 expression serves as a diagnostic biomarker of proliferation and metastasis of clear cell renal carcinoma.
Wang Y; Zhou X; Han P; Lu Y; Zhong X; Yang Y; Li D; Liu D; Li Q; Pan N; Mo Y; Luo W; Li P; Zhou X; Liudmila M
Pathol Res Pract; 2021 Apr; 220():153393. PubMed ID: 33740544
[TBL] [Abstract][Full Text] [Related]
34. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract][Full Text] [Related]
35. Leveraging diverse cell-death patterns to predict the prognosis, immunotherapy and drug sensitivity of clear cell renal cell carcinoma.
Zhang X; Zhang M; Song L; Wang S; Wei X; Shao W; Song N
Sci Rep; 2023 Nov; 13(1):20266. PubMed ID: 37985807
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide screening and cohorts validation identifying novel lncRNAs as prognostic biomarkers for clear cell renal cell carcinoma.
Zhang C; Huang D; Liu A; Xu Y; Na R; Xu D
J Cell Biochem; 2020 Mar; 121(3):2559-2570. PubMed ID: 31646670
[TBL] [Abstract][Full Text] [Related]
37. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.
Sun JX; Xia QD; Liu CQ; Xu JZ; Xun Y; Lu JL; Hu J; Wang SG
Dis Markers; 2021; 2021():8800358. PubMed ID: 34512816
[TBL] [Abstract][Full Text] [Related]
38. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
39. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
[TBL] [Abstract][Full Text] [Related]
40. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
